Navigation Links
Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France

100 Percent Purified Seawater Helps Users Breathe Freely

KENILWORTH, N.J., March 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced the launch of AFRIN(R) PureSea(TM) Hydrating Nasal Rinse, the only nasal rinse product entirely made of 100 percent purified sea water. Available in the cold/allergy aisle at retailers nationwide, AFRIN PureSea is clinically proven to cleanse nasal and sinus passages of mucus, pollutants, and irritants so users can breathe freely.

To view the Multimedia News Release, go to:

"Nasal rinsing is a simple technique to cleanse nasal and sinus passages while helping you to breathe freely," said Mary Jo DiMilia, M.D., an internist at Mount Sinai Medical Center in New York. "AFRIN PureSea is a new and convenient way to clean nasal passages, because it requires no mixing, minimal cleanup, and stays sterile even after the product is used."

The sea water in AFRIN PureSea is taken from the Bay of Saint-Malo in France, home to some of the most powerful tides in the world. The strong currents renew the composition of the water, oxygenating it and replenishing its mineral content. A gentle and effective nasal rinse, AFRIN PureSea is non-medicated, can be used daily and comes ready to use with a specially designed applicator that fits the shape of the nostrils.

"With consumers becoming more proactive about their health, Schering-Plough recognized the need for a convenient nasal irrigation product that is all-natural and easy to use at home," said Dr. John O'Mullane, group vice president, research and development, Schering-Plough Consumer Health Care. "The composition of the purified sea water in AFRIN PureSea is very similar to that of the human body, striking the right balance of salt, minerals, and elements to effectively rinse nasal and sinus passages with minimal discomfort or stinging."

AFRIN PureSea Nasal Rinse is available in three forms of delivery -- Medium Stream, Gentle Mist, and Ultra-Gentle Mist -- and can be found at most drug stores, mass retailers, and grocery stores nationwide. Both the Medium Stream and Gentle Mist are designed for use in adults and children ages 2 and older, and the Ultra-Gentle Mist is designed for use in children 6 months and older.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough, an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for AFRIN PureSea. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. "Risk Factors" in Schering-Plough's 2008 10-K, filed February 27, 2009.

SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. Video: Keppra XR(TM) Approved in the U.S.
10. Video: Fortune 1000 Executives: New President Must Fix Education Gap
11. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):